

Therapeutic Antibodies and Infectious Diseases

November 20th–22nd 2012, Tours

VINCI International Congress Centre, Loire Valley, France

Whether they target microbial or human antigens, therapeutic monoclonal antibodies revive the fields of clinical microbiology and infectious diseases. For the very first time, a congress aims to gather specialists from multiple disciplines to confront what has been learned from clinical experience and recent pre-clinical and clinical developments.



20th November – Afternoon

13:00 – 14:00 : Welcome

14:00 – 14:40 : Keynote lecture (I)

Chairman : Gilles Thibault

Title to be defined - *Jacques Banchereau (Pending)*

14:40 – 16:10 : Anti-bacterial antibodies (I)

Chairman : Philippe Thullier

Development of a recombinant IgG neutralizing the anthrax lethal toxin - *Thibaut Pelat, Grenoble, France*

Development of mAbs against the Panton-Valentine leucocidin from *Staphylococcus aureus* - *Dubravka Drabek, Rotterdam, The Netherlands*

Development of anti-staphylococcal enterotoxin mAbs - *Bradley Stiles, Wilson College, Chambersburg, Pennsylvania*

16:10 – 17:00 : Coffee break

17:00 – 18:30 : Anti-viral antibodies (I)

Chairman : Franis Barin

Mabs against henipaviruses (Hendra and Nipah viruses) - *Dimiter Dimitrov, Frederick, MD*

Post-exposure antibody prophylaxis protects non-human primates from filovirus disease - *John Dye, USAMRIID*

Isolation of scFVs targeting Marburg and Ebola viruses - *Jeffrey W. Froude, USAMRMC*

21st November : Morning

08:00 – 08:30 : Welcome

08:30 – 10:30 : Anti-viral antibodies (II)

Chairman : Mustapha Si-Tahar

Broadly neutralizing anti-influenza virus antibodies – *Jaap Goudsmit, Crucell, The Netherlands (Pending)*

Targeting HIV – *Pascal Poignard, Scripps research and IAVI (Pending)*

Targeting a latent viral infection: reasons of the failure of sevirumab, an anti-CMV Ab – *Adele M. Kaplan Gilpin, Johns Hopkins University, Batimore (Pending)*

Mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells – *Nikolai V. Naoumov, London, UK (Pending)*

10:30 – 11:00 : Coffee break

11:00 – 11:40 : Keynote lecture (II)

First approval of an engineered monoclonal antibody for the treatment of HTLV1 induced acute T cell leukemia – *Mitsuo Satoh, Kyowa, Japan (Pending)*

11:40 – 12:40 : Anti-bacterial antibodies (II)

Chairman : Dominique Buzoni-Gatel

Development of panobacumab, anti-*Pseudomonas aeruginosa* endotoxin - *Michael Rudolf, Kenta Biotech, Bern, Switzerland*

Development of recombinant polyclonal Abs against *Pseudomonas aeruginosa* – *Peter S. Andersen, Symphogen, Lyngby, Denmark*

21st November – Afternoon

12:40 – 14:00 : Lunch

14:00 – 15:00 : Anti-viral antibodies (III)

Chairman : Philippe Roingeard

Targeting CD4, a HIV receptor, with ibalizumab – Stanley Lewis, Taimed Biologics USA, Irvine (Pending)

Targeting HCV receptor – Mirjam Zeisel, Strasbourg, France

15:00 – 16:00 : Keynote lecture (III)

Regulatory aspects in the development of monoclonal antibody cocktails – Patrick G. Swann, FDA

16:00 – 16:30 : Coffee break

16:30 – 18:00 : Involvement of the French biotech industry in the field

Chairman : Jean-Luc Teillaud

Development of anti-Shiga toxin mAbs – Christian Behrens, LFB, France

The ISAAC and VIVA SCREEN platforms for the generation of human mAbs – Majid Mehtalis, Vivalis, Nantes, France

Monoclonal antibodies against infectious diseases at SANOFI: where are we? – Laurent Fraisse, SANOFI, France

20:00 : Gala dinner

22nd November : Morning

08:30 – 09:00 : Welcome

09:00 – 12:00 : Therapeutic antibodies and infectious diseases: a double edge sword?

Chairman : Yvon Lebranchu

Eculizumab in severe Shiga toxin-associated haemolytic and uremic syndromes (HUS) – Christian Combe, Bordeaux, France

Rituximab in mixed cryoglobulinemia secondary to hepatitis C virus infection – Marcella Visentini, Rome, Italy

Tuberculosis and other opportunistic infections during anti-TNF therapy, the French RATIO registry – Xavier Mariette, Paris, France

10:30 – 11:00 : Coffee break

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) – Patrick Vermersch, Lille, France

Belatacept (CTLA4-Ig) and risk of lymphoproliferation after EBV primo-infection – Bernard Charpentier, Paris, France

12:00 : Lunch

Location :

Vinci Internation Congress Centre
26 boulevard Heurteloup
37000 Tours, France

Website :

<http://www.taid.fr>

Registration fee :

Includes admission to the congress, the proceedings, coffee breaks and lunches.

- ✓ Academic : 200 €
- ✓ Industrial : 500 €
- ✓ Student : 100 €
- ✓ Cluster infectiologie or FeRI member : 80 €
- ✓ GDR ACCITH member : free
- ✓ Gala dinner : 60 €